283 related articles for article (PubMed ID: 34426176)
1. Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature.
Aragaki AK; Jing Y; Hoffman-Censits J; Choi W; Hahn NM; Trock BJ; McConkey DJ; Johnson BA
Eur Urol Oncol; 2022 Jun; 5(3):338-346. PubMed ID: 34426176
[TBL] [Abstract][Full Text] [Related]
2. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
3. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A; Bilen MA; Stewart T; Santos V; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
Eur Urol Oncol; 2021 Jun; 4(3):464-472. PubMed ID: 33423945
[TBL] [Abstract][Full Text] [Related]
4. The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.
Boll LM; Perera-Bel J; Rodriguez-Vida A; Arpí O; Rovira A; Juanpere N; Vázquez Montes de Oca S; Hernández-Llodrà S; Lloreta J; Albà MM; Bellmunt J
Sci Rep; 2023 Sep; 13(1):15287. PubMed ID: 37714872
[TBL] [Abstract][Full Text] [Related]
5. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors.
Deng B; Park JH; Ren L; Yew PY; Kiyotani K; Antic T; O'Connor K; O'Donnell PH; Nakamura Y
Cancer Rep (Hoboken); 2018 Jun; 1(1):e1002. PubMed ID: 32729250
[TBL] [Abstract][Full Text] [Related]
6. Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients.
Seitz RS; Hurwitz ME; Nielsen TJ; Bailey DB; Varga MG; Ring BZ; Metts CF; Schweitzer BL; McGregor K; Ross DT
J Transl Med; 2022 Aug; 20(1):370. PubMed ID: 35974414
[TBL] [Abstract][Full Text] [Related]
7. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
Yanagisawa T; Kawada T; Quhal F; Bekku K; Laukhtina E; Rajwa P; von Deimling M; Majdoub M; Chlosta M; Pradere B; Mori K; Kimura T; Schmidinger M; Karakiewicz PI; Shariat SF
World J Urol; 2023 Jul; 41(7):1763-1774. PubMed ID: 37209143
[TBL] [Abstract][Full Text] [Related]
8. Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
Wang L; Sfakianos JP; Beaumont KG; Akturk G; Horowitz A; Sebra RP; Farkas AM; Gnjatic S; Hake A; Izadmehr S; Wiklund P; Oh WK; Szabo PM; Wind-Rotolo M; Unsal-Kacmaz K; Yao X; Schadt E; Sharma P; Bhardwaj N; Zhu J; Galsky MD
Clin Cancer Res; 2021 Aug; 27(15):4287-4300. PubMed ID: 33837006
[TBL] [Abstract][Full Text] [Related]
9. Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.
Erlmeier F; Klümper N; Landgraf L; Strissel PL; Strick R; Sikic D; Taubert H; Wach S; Geppert CI; Bahlinger V; Breyer J; Ritter M; Bolenz C; Roghmann F; Erben P; Schwamborn K; Wirtz RM; Horn T; Wullich B; Hölzel M; Hartmann A; Gschwend JE; Weichert W; Eckstein M
Eur Urol; 2023 Feb; 83(2):133-142. PubMed ID: 36372626
[TBL] [Abstract][Full Text] [Related]
10. Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment.
Jin J; Li J; Peng C; Chen J; Xu G; Pan S
Anticancer Drugs; 2023 Jul; 34(6):797-802. PubMed ID: 36729952
[TBL] [Abstract][Full Text] [Related]
11. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
12. A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Jang HJ; Hostetter G; Macfarlane AW; Madaj Z; Ross EA; Hinoue T; Kulchycki JR; Burgos RS; Tafseer M; Alpaugh RK; Schwebel CL; Kokate R; Geynisman DM; Zibelman MR; Ghatalia P; Nichols PW; Chung W; Madzo J; Hahn NM; Quinn DI; Issa JJ; Topper MJ; Baylin SB; Shen H; Campbell KS; Jones PA; Plimack ER
Clin Cancer Res; 2023 Jun; 29(11):2052-2065. PubMed ID: 36928921
[TBL] [Abstract][Full Text] [Related]
13. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition.
Necchi A; Raggi D; Gallina A; Bandini M; de Jong JJ; Marandino L; Briganti A; Montorsi F; Davicioni E; Lotan Y; Gibb EA
Urol Oncol; 2021 Oct; 39(10):734.e11-734.e17. PubMed ID: 34301456
[TBL] [Abstract][Full Text] [Related]
15. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
[TBL] [Abstract][Full Text] [Related]
17. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
18. Single-cell atlases link macrophages and CD8
Liang Y; Tan Y; Guan B; Guo B; Xia M; Li J; Shi Y; Yu Z; Zhang Q; Liu D; Yang X; Hao J; Gong Y; Shakeel M; Zhou L; Ci W; Li X
Theranostics; 2022; 12(18):7745-7759. PubMed ID: 36451860
[No Abstract] [Full Text] [Related]
19. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
20. Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI).
Szabados B; Ponz-Sarvisé M; Machado R; Saldana D; Kadel EE; Banchereau R; Bouquet F; Garmhausen M; Powles T; Schröder C;
Clin Cancer Res; 2022 Sep; 28(18):4083-4091. PubMed ID: 35877091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
